Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.
Ontology highlight
ABSTRACT: Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.
SUBMITTER: Page DB
PROVIDER: S-EPMC6783471 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA